AbCellera Biologics
ABCL
161 hedge funds and large institutions have $1.26B invested in AbCellera Biologics in 2022 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 53 increasing their positions, 28 reducing their positions, and 21 closing their positions.
157% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 21
101% more call options, than puts
Call options by funds: $38M | Put options by funds: $18.9M
89% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 28
24% more funds holding
Funds holding: 130 → 161 (+31)
14% more capital invested
Capital invested by funds: $1.1B → $1.26B (+$160M)
1.55% more ownership
Funds ownership: 39.97% → 41.52% (+1.6%)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$79.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$24.8M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$19.5M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$14.6M |
| 5 |
Millennium Management
New York
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DB
DCVC Bio
Palo Alto,
California
|
-$61.6M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$44.3M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$25.6M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$8.34M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$4.32M |
ABCL Hedge Fund Activity: Q2 2022 in Review
161 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q2 2022, worth a combined $1.26B — up 14% from $1.1B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new ABCL positions and 21 closed out — a net gain of 33 holders — while 53 added to existing stakes and 28 trimmed.
The largest buyer was BlackRock, adding an estimated $79.4M. The largest seller was DCVC Bio, cutting an estimated $61.6M.
- 161 institutional investors held AbCellera Biologics (ABCL) as of Q2 2022, up from 130 in Q1 2022.
- Funds reported $1.26B of AbCellera Biologics stock for Q2 2022, up 14% quarter-over-quarter.
- 54 funds opened new AbCellera Biologics positions in Q2 2022 and 21 closed out, a net change of +33 holders.
- The largest AbCellera Biologics buyer in Q2 2022 was BlackRock, an estimated $79.4M added.
- The largest AbCellera Biologics seller in Q2 2022 was DCVC Bio, an estimated $61.6M sold.
Based on aggregated 13F filings for Q2 2022.